Avicanna Inc. (TSX:AVCN)

Canada flag Canada · Delayed Price · Currency is CAD
0.185
0.00 (0.00%)
At close: Mar 9, 2026
-33.93%
Market Cap 23.27M
Revenue (ttm) 25.50M
Net Income (ttm) -1.88M
Shares Out 125.79M
EPS (ttm) -0.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 153,750
Average Volume 64,534
Open 0.190
Previous Close 0.185
Day's Range 0.185 - 0.190
52-Week Range 0.150 - 0.390
Beta 0.26
RSI 48.33
Earnings Date Mar 31, 2026

About Avicanna

Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for consumer, medical, and pharmaceutical markets in Canada and internationally. It provides medical cannabis formulary products, including oral, sublingual, topical, and transdermal deliveries with various ratios of cannabinoids under the RHO Phyto brand; and indication-specific pharmaceutical products to address unmet medical needs in the areas of de... [Read more]

Sector Healthcare
Founded 2016
Employees 87
Stock Exchange Toronto Stock Exchange
Ticker Symbol AVCN
Full Company Profile

Financial Performance

In 2024, Avicanna's revenue was 25.46 million, an increase of 51.62% compared to the previous year's 16.79 million. Losses were -3.62 million, -58.62% less than in 2023.

Financial Statements

News

There is no news available yet.